泡上云霄前的轰隆轰隆
The roar before the launch
大家新年好!
在己🀅经再迎2023年的美好时光时间,最先向所有工人和相互合作ꦚ朋友们们衷心祝愿我非常诚恳的请安和非常感谢!
博鱼体育app 的202在一年正是因为你要每一项位的直接参与而奇异和出彩。
新冠新冠肺炎的不设确保,让 202在一年下来己经是具有对决的一年下来。但也这是因为这一些对决和不设确保,让你们觉得相对友爱、庞大,ꩵ不怕未来的发展。
Hi Everyone,
I hope y𓆉our holiday season is off to a bright start!
As 2021 draౠws to a close, I would like to take the opportunity to look back at some of my favorite moments from 2021, and express my sincere appreciation to our employees and our external﷽ partners. Without each one of you, we would not have been where we are today and together, we are building our company from the ground up. Thank you!
2021 is another year filled with challe🀅nges as we continue to experience the uncertainties of the COVID-19 pandemic. As we continue to navigate uncharted🌠 waters, we, as a close knit team with a mission to create are growing stronger as each day goes by.
……………………………………………………………………………………………………………………………༒…………𓄧…………..
在博鱼体育app 与systimmune全体成员营业员的执著认真下,博鱼体育app 的SEBA双特异形抗原手机服务品台、GNC多特异形抗原手机服务品台、SHRI-ADC药手机服务品台都确认了公里数碑式的挑战。
未来三年时间内,博鱼体育app 就已经有8个全.球先进的不断创新药己经从临床药学奋勇前进入到临床药学实验室检测步骤。其中包括双抗SI-B001、SI-B003,四抗GNC-038、GNC-039、GNC-035,及双抗ADC制剂BL-B01D1,和SI-F019。
The entire team at SystImmune rem🌄ained focused on innovative science in our drug development and our collaborative work with Baili’s R&D team has both deepened in the subject matters and widened in scope. As many of you know, this year marked a therapeutic milestone for our antibody drug conjugate capabilities. Importantly, we made major progress on the next generation development of GNC, which effectively solidified our leadership in multi-specific therapeutic antibody technology in oncology.
首个进行临床上上探索分析的双特女性朋友抵抗能力 SI-B001(EGFR X Her3)在12月进行了II期,并刚刚启动时SI𓆏-B001与泰瑞沙(奥西替尼)联办方法的临床上上探索分析好项目。另一将要I 期做实验的时候𝔍步骤的抵抗能力类药,也都通过既定目标记划顺畅落实。
Progressing from preclinical development into clinical trials is the result of our efficient Execution of a long-planned strategy. Currently, we have 7 molecules in Phase I or II clinical trials in China, including SI-B001, SI-B003, SI-F019, GNC-038, GNC-039, GNC-035, and BL-B01D1. Our first project, SI-B001, targeting EGFR and Her3 with a bispecific tetravalent, started enrollment for Phase II in December 2021, a pivotal milestone for oncology therapeutic testing. In addition, just a few days ago, we kicked off our collaborative relationship with AstraZeneca in connection with the clinical studying of SI-B001 in combination with TAGRISSO (osim🦄ertinib).
双抗ADC治疗肿瘤治疗药物BL-B01D1在5月将建IND 这是们的另一两个个公里数碑,愈发应当欣慰的是,BL-B01D1早已经于14月在中山大学本科肿癌医院科室非常成功入组首个女性。第一个AD🌞C治疗肿瘤治疗药物,BL-M02D1(Trop2)行将IND,再次个ADC治疗肿瘤治疗药物也将而且pre-IND。
The advanced approach of BL-B01D1 is our firs♏t bispecific ADC that received IND approval, which is another milestone. Not long after its IND approval in October, we accepted the first patient for the Phase I trial in December 2021. TROP2 specific agent is the second ADC in line and it is currently in pre-IND. All other active Phase I trials have shown no cause for safety related delays and are underway as planned.
SI-B001也已♓在USA的加载了报名IND,并即将于明年中得到FDA的报批。意大利的临床上检验发🌼展与临床上检验深入分析组织的汇聚事业也在按时参与中。
As you may know, recently we have partnered with a U.S♏. based CRO 🌠to initiate our first US IND for SI-B001 drug. Our goal is to receive FDA approval of the IND around mid-2022. In the meantime, we have started to build up our U.S. clinical development team to bring in U.S. trial management capabilities onsite at SystImmune. With more clinical data to be generated and collected in 2022, we will be well position to advance our current research projects and to get closer to our mission of bringing new drugs and innovation to cancer treatment.
…………………………………………………………………………………………………………………………………………♌…….
即便博鱼体育app 和Systimmune相隔一款太阳系,却仍如果博鱼体育app 存在主体的神圣职责--为淋巴肿瘤改善带去进阶性的作用的信息化药,而紧跟着相互。我替享有这般一款智识、专业、贡献的项目团队而有狂妄。盼望着博鱼体育app 能够挺快第一次见面,在下一款的关键过去了之刻,主体举杯邀欢庆。
感谢博鱼体育app 所有合作伙伴一直以来的支持和关心!
道谢博鱼体育app 临床治疗深入分析创业项目所有的参研重心的每一位深入分析者的信赖与付诸!
感谢信博鱼体育app 所有公司职员在2022年的始终和埋头苦干!
新春佳节快乐时光!瞩目博鱼体育app 会享用一些变得更加美味开心的2023年!
I am so proud to have such a great team and I enjoy working with you all🐠 even though we are half a world apart. For💫 those that I have not met in person, I am eager to know you more and to meet you in person next year. Your talent, work ethics, and your devotion to science and to our mission inspire me.
At the same time, I would also like to thank our🏅 partners, including corporate attorney Qingqing, and our patent lawyer Dr. Connie Wang and Dr. Yangsong Gu, and our HR Taylor for their high quality professional services.
Thank you again for all your effort and dedication in 2021. We look forward to another prosperous year in 2022. I wish you all a warm𝄹 and healthy holiday season and a happy 2022.
Sincerely,
Yi Zhu
President & CEO
股东长:朱义